Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Pulmatrix, Inc. (NASDAQ: PULM).

Full DD Report for PULM

You must become a subscriber to view this report.


Recent News from (NASDAQ: PULM)

Pulmatrix selected to present company profile at the 2018 Respiratory Innovation Summit in San Diego
LEXINGTON, Mass. , May 17, 2018 /PRNewswire/ --  Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases has been selected to present at the 2018 Respiratory Innovation Summit at the Man...
Source: PR Newswire
Date: May, 17 2018 09:35
Pulmatrix Reports Q1 2018 Results
LEXINGTON, Mass. , May 11, 2018 /PRNewswire/ --  Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter results. "We reached a major milestone for our Pulmazole program in the first quarter with the initiation of dosing in our phase 1/ 1b study. With a financing t...
Source: PR Newswire
Date: May, 11 2018 09:00
Your Daily Pharma Scoop: Heron Offering, Sorrento Issues Letter To Shareholders, MediciNova Setback
Today we will discuss Heron Therapeutics (HRTX), which saw a sharp pullback initially as it announced a secondary offering. Shares have bounced back in midday trading and were up more than 1%, at last check. Heron has priced the offering of 6 million shares of its common stock at $26 per s...
Source: SeekingAlpha
Date: March, 30 2018 08:00
Pulmatrix down 26% premarket on pricing public offering of 23.5M units
Pulmatrix (NASDAQ: PULM ) prices its public offering of 23.5M units, comprised of one share of common stock and one Series A and one Series B warrant to purchase one share of common stock, for the gross proceeds of ~$15.2M. More news on: Pulmatrix, Inc., Healthcare stocks news, Stocks on...
Source: SeekingAlpha
Date: March, 29 2018 07:49
Pulmatrix Announces Pricing Of $15.2 Million Underwritten Public Offering
LEXINGTON, Mass. , March 29, 2018 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the pricing of an underwritten public offering of an aggregate of 23,500,000 units. Each unit is comprised of one share of common stock (or co...
Source: PR Newswire
Date: March, 29 2018 00:02
Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook on Pulmonary Disease Pipeline
LEXINGTON, Mass. , March 13, 2018 /PRNewswire/ --  Pulmatrix, Inc . (NASDAQ: PULM) today announces 2017 financial results, reviews the Company's recent progress, and provides an outlook for its pulmonary disease development pipeline. "The Company continues to advance its iS...
Source: PR Newswire
Date: March, 13 2018 16:43
Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE(TM) Formulation of Itraconazole
LEXINGTON, Mass. , Feb. 12, 2018 /PRNewswire/ --  Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that the single dose escalation phase of the first-in-human stud...
Source: PR Newswire
Date: February, 12 2018 09:35
Premarket analyst action - healthcare
Pulmatrix (NASDAQ: PULM ) initiated with Buy rating and $5 (228% upside) price target at H.C. Wainwright. More news on: Pulmatrix, Inc., Aquinox Pharmaceuticals, Inc., Aclaris Therapeutics, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: February, 09 2018 08:15
Today's Research Reports on Trending Tickers: Atossa Genetics and Pulmatrix
NEW YORK, NY / ACCESSWIRE / January 29, 2018 / All three major indexes closed the week at record highs Friday as corporate earnings continue to impress investors. The Dow Jones Industrial Average gained 0.85 percent to close at 26,616.71, while the S&P 500 Index jumped 1.18 percent to c...
Source: ACCESSWIRE IA
Date: January, 29 2018 08:00
Midday Gainers / Losers (1/26/2018)
Gainers: BSPM +66% . OASM +48% . CAPR +25% . RDHL +19% . ABAX +18% . PULM +18% . WRLD +16% . VMW +14% . FWP +14% . MYSZ +13% . More news on: Biostar Pharmaceutic, Oasmia Pharmaceutical, Capricor Therapeutics, Inc., Stocks on the move, Read more ...
Source: SeekingAlpha
Date: January, 26 2018 12:40

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-180.460.46220.4650.4423576,624
2018-05-170.4640.4596920.490.452,785,278
2018-05-160.4750.45630.4750.45345,121
2018-05-150.4590.45980.4692780.450247301,835
2018-05-140.4410.45480.45580.441225,942

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-18168,552332,41150.7059Short
2018-05-17578,4951,640,74435.2581Short
2018-05-1693,113234,31239.7389Short
2018-05-1556,351128,95043.6999Short
2018-05-1436,754114,75532.0282Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PULM.


About Pulmatrix, Inc. (NASDAQ: PULM)

Logo for Pulmatrix, Inc. (NASDAQ: PULM)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $18,561,181 - 05/11/2018
  • Authorized: 100,000,000 - 05/01/2018
  • Issue and Outstanding: 41,927,221 - 05/01/2018

 


Recent Filings from (NASDAQ: PULM)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 26 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 13 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: April, 12 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: April, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 04 2018
Prospectus filed under Rule 424(b)(4)
Filing Type: 424B4Filing Source: edgar
Filing Date: March, 30 2018

 

 


Daily Technical Chart for (NASDAQ: PULM)

Daily Technical Chart for (NASDAQ: PULM)


Stay tuned for daily updates and more on (NASDAQ: PULM)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: PULM)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PULM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of PULM and does not buy, sell, or trade any shares of PULM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/